CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Mr. Paul Mckenzie es el Chief Executive Officer de CSL Ltd, se unió a la empresa desde 2019.
¿Qué tal es el rendimiento del precio de la acción CSL LTD?
El precio actual de CSL LTD es de $100.39, ha aumentado un 3.81% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de CSL Ltd?
CSL Ltd pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de CSL Ltd?
La capitalización bursátil actual de CSL Ltd es $48.7B
¿Es CSL Ltd una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 19 analistas han realizado calificaciones de análisis para CSL Ltd, incluyendo 5 fuerte compra, 10 compra, 6 mantener, 0 venta, y 5 fuerte venta